CD22 and precursor B-cell acute lymphoblastic leukemia: Additionally, in our previous study, we found the ORRs of patients with B-ALL and DLBCL treated with CD19/CD22 CAR T cell infusions in our department to be 96.0% and 72.2%, respectively (18).